Cholecalciferol supplementation improves suppressive capacity of regulatory T-cells in young patients with new-onset type 1 diabetes mellitus - A randomized clinical trial.
It is unknown if cholecalciferol is able to modify defects in regulatory T cells (Tregs) in type 1 diabetes (T1D). In this randomized, double-blind, placebo controlled trial 30 young patients with new-onset T1D were assigned to cholecalciferol (70IU/kgbodyweight/day) or placebo for 12months. Tregs were determined by FACS-analysis and functional tests were assessed with ex vivo suppression co-cultures at months 0, 3, 6 and 12. Suppressive capacity of Tregs increased (p<0.001) with cholecalciferol from baseline (-1.59±25.6%) to 3 (30.5±39.4%), 6 (44.6±23.8%) and 12months (37.2±25.0%) and change of suppression capacity from baseline to 12months was significantly higher (p<0.05) with cholecalciferol (22.2±47.2%) than placebo (-16.6±21.1%). Serum calcium and parathormone stayed within normal range. This is the first study, which showed that cholecalciferol improved suppressor function of Tregs in patients with T1D and vitamin D could serve as one possible agent in the development of immunomodulatory combination therapies for T1D.
Division of Endocrinology and Metabolism, Medical University Graz, Auenbruggerplatz 15, 8036 Graz, Austria. Electronic address: gerlies.treiber@medunigraz.at.
Gerlies
G
Treiber
Division of Endocrinology and Metabolism, Medical University Graz, Auenbruggerplatz 15, 8036 Graz, Austria. Electronic address: barbara.prietl@medunigraz.at.
Barbara
B
Prietl
Department of General Paediatrics, Medical University Graz, Auenbruggerplatz 34, 8036 Graz, Austria. Electronic address: elke.froehlich-reiterer@medunigraz.at.
Elke
E
Fröhlich-Reiterer
Division of Endocrinology and Metabolism, Medical University Graz, Auenbruggerplatz 15, 8036 Graz, Austria. Electronic address: evelyne.lechner@medunigraz.at.
Evelyne
E
Lechner
Division of Endocrinology and Metabolism, Medical University Graz, Auenbruggerplatz 15, 8036 Graz, Austria. Electronic address: anja.ribitsch@medunigraz.at.
Anja
A
Ribitsch
Department of Paediatrics, Medical University Vienna, Währinger Gürtel 18-20, 1090 Wien, Austria. Electronic address: maria.fritsch@meduniwien.ac.at.
Maria
M
Fritsch
Department of Paediatrics, Medical University Vienna, Währinger Gürtel 18-20, 1090 Wien, Austria. Electronic address: Birgit.Rami@meduniwien.ac.at.
Birgit
B
Rami-Merhar
Department of Paediatrics, Paracelsus Medical University Salzburg, Müllner Hauptstraße 48, 5020 Salzburg, Austria. Electronic address: c.steigleder-schweiger@salk.at.
Claudia
C
Steigleder-Schweiger
Division of Rheumatology and Immunology, Medical University Graz, Auenbruggerplatz 15, 8036 Graz, Austria. Electronic address: winfried.graninger@medunigraz.at.
Winfried
W
Graninger
Department of General Paediatrics, Medical University Graz, Auenbruggerplatz 34, 8036 Graz, Austria. Electronic address: martin.borkenstein@medunigraz.at.
Martin
M
Borkenstein
Division of Endocrinology and Metabolism, Medical University Graz, Auenbruggerplatz 15, 8036 Graz, Austria. Electronic address: thomas.pieber@medunigraz.at.
Thomas R
TR
Pieber
D000293:Adolescent; D002096:C-Peptide / Q000097:blood; D002648:Child; D002762:Cholecalciferol / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D019587:Dietary Supplements; D004311:Double-Blind Method; D005215:Fasting / Q000097:blood; D005260:Female; D006801:Humans; D008297:Male; D010865:Pilot Projects; D011446:Prospective Studies; D050378:T-Lymphocytes, Regulatory / Q000187:drug effects* / Q000276:immunology; D013997:Time Factors; D016896:Treatment Outcome; D014815:Vitamins / Q000008:administration & dosage / Q000627:therapeutic use
D002096:C-Peptide; D014815:Vitamins; D002762:Cholecalciferol
Cholecalciferol; Randomized controlled trial; Regulatory T cells; Suppressive capacity; Type 1 diabetes; Vitamin D